Merck & Company (MRK) 58.34 $MRK
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 11.61 (+0.17), BLCM: 22.65 (+0.19), KITE: 59.98 (+0.20), MRK: 58.34 (+0.59), CLLS: 35.20 (+0.20), XON: 46.30 (+3.30), AMGN: 164.30 (+1.71), JUNO: 60.75 (+4.15)
Next Resistance Level for Merck (MRK) is $58.47
Comtex SmarTrend(R) - Mon Mar 30, 10:19AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $57.87 today and have reached the first resistance level of $58.11. Analysts will be watching for a cross of the next upside pivot targets of $58.47 and $59.07.
MRK: 58.34 (+0.59)
Drafting and Managing Pharmaceutical Safety Data Exchange Agreements Seminar, London UK - 14th May 2015
M2 - Mon Mar 30, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brgxr3/drafting_and) has announced the addition of the "Drafting and Managing Pharmaceutical Safety Data Exchange Agreements (Seminar, London)" conference to their offering. Ensuring the inclusion of key pharmacovigilance-relevant terms in agreements and monitoring compliance with them can be challenging, but is essential for compliance with current regulatory requirements relating to medicinal products. This seminar will address the key regulatory requirements relating to pharmacovigilance and discuss how to ensure that they are taken into account in various types of commercial arrangements. The emphasis will be on identifying the key terms needed in different types of agreement with a view to ensuring regulatory compliance and on a practical approach to drafting. The effective management of pharmacovigilance aspects of commercial agreements is challenging but essential. This one day Drafting and Managing Pharmaceutical Safety Data Exchange Agreements seminar will enable attendees to: - Understand the different types of commercial arrangements in the pharmaceutical industry - Gain an overview of contracts - Find out about the regulatory requirements and guidance on pharmacovigilance relevant to commercial agreements Speakers - Christine Bendall, Pharview Ltd - Margaret Walters, Merck Sharp & Dohme Ltd For more information visit http://www.researchandmarkets.com/research/br...afting_and
MRK: 58.34 (+0.59)
OncoSec Medical Has A Promising Technology
Clinically Sound Investor - at Seeking Alpha - Mon Mar 30, 8:18AM CDT
MRK: 58.34 (+0.59), BMY: 65.76 (+0.50)
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer
PR Newswire - Mon Mar 30, 7:45AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Tom Cannell has joined as Chief Commercial Officer. As the Company prepares for global commercialization of Contrave® /Mysimba(TM) (naltrexone HCl / bupropion HCl extended release), Cannell will lead all aspects of Orexigen's global commercial strategy, assuming responsibilities previously held by Mark Booth. After successfully leading Orexigen's commercial effort through the U.S. launch of Contrave, Booth plans to leave Orexigen later this year to pursue opportunities closer to his home in Chicago.
OREX: 7.75 (+0.21), MRK: 58.34 (+0.59)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 11.61 (+0.17), MRK: 58.34 (+0.59), XON: 46.30 (+3.30)
Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation (NYSE: XON), today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
MRK: 58.34 (+0.59), XON: 46.30 (+3.30)
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
MRK: 58.34 (+0.59), XON: 46.30 (+3.30)
Berkshire Hathaway Is Terrific - Cramer's Lightning Round (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 5:02AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, March 27. Bullish Calls: Box (NYSE: BOX ): "I think Aaron Levie did okay. Honestly, if I would have told that story, it would have had a much better...
TTPH: 37.98 (+1.83), BOX: 19.05 (+0.75), MRK: 58.34 (+0.59), FUEL: 9.24 (-0.19), GOOGL: 561.13 (+3.58), BRK.B: 145.98 (+2.09), BRK.A: 219,700.00 (+2,699.92), GOOG: 552.03 (+3.69), ADBE: 73.60 (+0.29)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
M2 - Mon Mar 30, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d4nggb/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering. The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019. CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators. An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market. According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually. Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market. Key Vendors - AbbVie - Astra Zeneca - Biogen Idec - Johnson & Johnson - Takeda Pharmaceutical - UCB Other Prominent Vendors - Amgen - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - CD Pipeline Landscape - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/d4...bal_crohns
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), NVO: 54.68 (+0.84), MRK: 58.34 (+0.59), AMGN: 164.30 (+1.71), NVS: 101.31 (+0.91)
Gardasil 9 Gets Positive Review from European Committee; The Center for the Biology of Chronic Disease (CBCD) Reviews a Report
PRWeb - Sun Mar 29, 11:02PM CDT
"Infected with the human papillomavirus (HPV)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement." - Greg Bennett, CBCD
MRK: 58.34 (+0.59)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), IBB: 351.32 (+3.86), ABBV: 58.24 (+0.59)
Merck: Buyback Plan Not As Impressive As It Appears
Stone Fox Capital - at Seeking Alpha - Sun Mar 29, 2:44AM CDT
MRK: 58.34 (+0.59)
Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently Hold for the Next 10 Years
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 28, 1:02PM CDT
Source: Centers for Disease Control and Prevention, Facebook. Few sectors are as hard to get a handle on as healthcare. Unlike traditional valuation metrics that allow Wall Street and investors to decipher whether a company could be trading...
JNJ: 101.55 (+1.21), PFE: 35.00 (+0.47), MRK: 58.34 (+0.59), GSK: 47.20 (+0.18), BMY: 65.76 (+0.50)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 73.47 (+3.16), BIIB: 431.62 (+1.75), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), HUM: 181.18 (+3.66), MEIP: 1.75 (+0.01), DVA: 82.17 (+0.34), PFS: 18.69 (+0.28), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), CLLS: 35.20 (+0.20), HHS: 7.84 (+0.08), OHRP: 2.81 (+0.07), THRX: 16.60 (+0.14), REGN: 459.78 (+5.28)
Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 1:40PM CDT
Immune Design (IMDZ) announced that it has started dosing patients in a phase Ib study on its immuno-oncology candidate, CMB305.
CYTK: 7.10 (-0.06), IMDZ: 22.77 (-1.32), MRK: 58.34 (+0.59), BMY: 65.76 (+0.50)
Ebola vaccine candidates pass safety test in in Liberia trials
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:19AM CDT
MRK: 58.34 (+0.59), NLNK: 56.40 (+4.14), GSK: 47.20 (+0.18)
Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020
M2 - Fri Mar 27, 7:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dv95g/albumin) has announced the addition of the "Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth. The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter). CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Albumin Market Overview Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 - 2020 Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020 Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020 Chapter 7 Recommendations Chapter 8 Company Profiles - CSL Behring LLC - HiMedia Laboratories - InVitria (Ventria Bioscience) - MedxBio Pte. Ltd. - Mitsubishi Tanabe Pharma - Novozymes A/S - Octapharma AG - RayBiotech, Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/5dv95g/albumin
BIIB: 431.62 (+1.75), SIAL: 138.41 (+0.20), MRK: 58.34 (+0.59)
Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
Business Wire - Fri Mar 27, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April 28. During the call, company executives will provide an overview of Merck's performance for the quarter.
MRK: 58.34 (+0.59)
Is This Tiny Biotech Still a Buy at All-Time Highs?
Maxx Chatsko, The Motley Fool - Motley Fool - Fri Mar 27, 6:58AM CDT
Does a soaring stock price mean investors should stay away or jump on the bandwagon? Well, it depends. Investors need to consider a multitude of factors, including financial metrics, growth rates, market opportunities, management style, competitive...
RGEN: 30.81 (+0.24), GE: 25.12 (+0.26), MRK: 58.34 (+0.59)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 11.61 (+0.17), BLCM: 22.65 (+0.19), KITE: 59.98 (+0.20), MRK: 58.34 (+0.59), CLLS: 35.20 (+0.20), XON: 46.30 (+3.30), AMGN: 164.30 (+1.71), JUNO: 60.75 (+4.15)
Next Resistance Level for Merck (MRK) is $58.47
Comtex SmarTrend(R) - Mon Mar 30, 10:19AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $57.87 today and have reached the first resistance level of $58.11. Analysts will be watching for a cross of the next upside pivot targets of $58.47 and $59.07.
MRK: 58.34 (+0.59)
Drafting and Managing Pharmaceutical Safety Data Exchange Agreements Seminar, London UK - 14th May 2015
M2 - Mon Mar 30, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brgxr3/drafting_and) has announced the addition of the "Drafting and Managing Pharmaceutical Safety Data Exchange Agreements (Seminar, London)" conference to their offering. Ensuring the inclusion of key pharmacovigilance-relevant terms in agreements and monitoring compliance with them can be challenging, but is essential for compliance with current regulatory requirements relating to medicinal products. This seminar will address the key regulatory requirements relating to pharmacovigilance and discuss how to ensure that they are taken into account in various types of commercial arrangements. The emphasis will be on identifying the key terms needed in different types of agreement with a view to ensuring regulatory compliance and on a practical approach to drafting. The effective management of pharmacovigilance aspects of commercial agreements is challenging but essential. This one day Drafting and Managing Pharmaceutical Safety Data Exchange Agreements seminar will enable attendees to: - Understand the different types of commercial arrangements in the pharmaceutical industry - Gain an overview of contracts - Find out about the regulatory requirements and guidance on pharmacovigilance relevant to commercial agreements Speakers - Christine Bendall, Pharview Ltd - Margaret Walters, Merck Sharp & Dohme Ltd For more information visit http://www.researchandmarkets.com/research/br...afting_and
MRK: 58.34 (+0.59)
OncoSec Medical Has A Promising Technology
Clinically Sound Investor - at Seeking Alpha - Mon Mar 30, 8:18AM CDT
MRK: 58.34 (+0.59), BMY: 65.76 (+0.50)
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer
PR Newswire - Mon Mar 30, 7:45AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Tom Cannell has joined as Chief Commercial Officer. As the Company prepares for global commercialization of Contrave® /Mysimba(TM) (naltrexone HCl / bupropion HCl extended release), Cannell will lead all aspects of Orexigen's global commercial strategy, assuming responsibilities previously held by Mark Booth. After successfully leading Orexigen's commercial effort through the U.S. launch of Contrave, Booth plans to leave Orexigen later this year to pursue opportunities closer to his home in Chicago.
OREX: 7.75 (+0.21), MRK: 58.34 (+0.59)
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
GlobeNewswire - Mon Mar 30, 7:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM.
ZIOP: 11.61 (+0.17), MRK: 58.34 (+0.59), XON: 46.30 (+3.30)
Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation (NYSE: XON), today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
MRK: 58.34 (+0.59), XON: 46.30 (+3.30)
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
PR Newswire - Mon Mar 30, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
MRK: 58.34 (+0.59), XON: 46.30 (+3.30)
Berkshire Hathaway Is Terrific - Cramer's Lightning Round (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 5:02AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, March 27. Bullish Calls: Box (NYSE: BOX ): "I think Aaron Levie did okay. Honestly, if I would have told that story, it would have had a much better...
TTPH: 37.98 (+1.83), BOX: 19.05 (+0.75), MRK: 58.34 (+0.59), FUEL: 9.24 (-0.19), GOOGL: 561.13 (+3.58), BRK.B: 145.98 (+2.09), BRK.A: 219,700.00 (+2,699.92), GOOG: 552.03 (+3.69), ADBE: 73.60 (+0.29)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
M2 - Mon Mar 30, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d4nggb/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering. The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019. CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators. An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market. According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually. Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market. Key Vendors - AbbVie - Astra Zeneca - Biogen Idec - Johnson & Johnson - Takeda Pharmaceutical - UCB Other Prominent Vendors - Amgen - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - CD Pipeline Landscape - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/d4...bal_crohns
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), NVO: 54.68 (+0.84), MRK: 58.34 (+0.59), AMGN: 164.30 (+1.71), NVS: 101.31 (+0.91)
Gardasil 9 Gets Positive Review from European Committee; The Center for the Biology of Chronic Disease (CBCD) Reviews a Report
PRWeb - Sun Mar 29, 11:02PM CDT
"Infected with the human papillomavirus (HPV)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement." - Greg Bennett, CBCD
MRK: 58.34 (+0.59)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), IBB: 351.32 (+3.86), ABBV: 58.24 (+0.59)
Merck: Buyback Plan Not As Impressive As It Appears
Stone Fox Capital - at Seeking Alpha - Sun Mar 29, 2:44AM CDT
MRK: 58.34 (+0.59)
Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently Hold for the Next 10 Years
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 28, 1:02PM CDT
Source: Centers for Disease Control and Prevention, Facebook. Few sectors are as hard to get a handle on as healthcare. Unlike traditional valuation metrics that allow Wall Street and investors to decipher whether a company could be trading...
JNJ: 101.55 (+1.21), PFE: 35.00 (+0.47), MRK: 58.34 (+0.59), GSK: 47.20 (+0.18), BMY: 65.76 (+0.50)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 73.47 (+3.16), BIIB: 431.62 (+1.75), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), HUM: 181.18 (+3.66), MEIP: 1.75 (+0.01), DVA: 82.17 (+0.34), PFS: 18.69 (+0.28), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), CLLS: 35.20 (+0.20), HHS: 7.84 (+0.08), OHRP: 2.81 (+0.07), THRX: 16.60 (+0.14), REGN: 459.78 (+5.28)
Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 1:40PM CDT
Immune Design (IMDZ) announced that it has started dosing patients in a phase Ib study on its immuno-oncology candidate, CMB305.
CYTK: 7.10 (-0.06), IMDZ: 22.77 (-1.32), MRK: 58.34 (+0.59), BMY: 65.76 (+0.50)
Ebola vaccine candidates pass safety test in in Liberia trials
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:19AM CDT
MRK: 58.34 (+0.59), NLNK: 56.40 (+4.14), GSK: 47.20 (+0.18)
Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020
M2 - Fri Mar 27, 7:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dv95g/albumin) has announced the addition of the "Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth. The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter). CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Albumin Market Overview Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 - 2020 Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020 Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020 Chapter 7 Recommendations Chapter 8 Company Profiles - CSL Behring LLC - HiMedia Laboratories - InVitria (Ventria Bioscience) - MedxBio Pte. Ltd. - Mitsubishi Tanabe Pharma - Novozymes A/S - Octapharma AG - RayBiotech, Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/5dv95g/albumin
BIIB: 431.62 (+1.75), SIAL: 138.41 (+0.20), MRK: 58.34 (+0.59)
Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
Business Wire - Fri Mar 27, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April 28. During the call, company executives will provide an overview of Merck's performance for the quarter.
MRK: 58.34 (+0.59)
Is This Tiny Biotech Still a Buy at All-Time Highs?
Maxx Chatsko, The Motley Fool - Motley Fool - Fri Mar 27, 6:58AM CDT
Does a soaring stock price mean investors should stay away or jump on the bandwagon? Well, it depends. Investors need to consider a multitude of factors, including financial metrics, growth rates, market opportunities, management style, competitive...
RGEN: 30.81 (+0.24), GE: 25.12 (+0.26), MRK: 58.34 (+0.59)
